Oxycodone is a centrally acting opioid analgesic whose interaction with μ-opioid receptors inhibits adenylate cyclase and activates potassium conductance, collectively hyperpolarising pain-signalling neurons in the spinal cord and brainstem. The degree of μ-receptor selectivity relative to κ and δ subtypes determines the ratio of analgesia to dysphoric and diuretic side effects. As a pharmacologically potent opioid compound, Oxycodone requires occupational exposure controls grounded in pharmacodynamic endpoint assessment rather than conventional organ toxicity thresholds.
Genotoxicity data for Oxycodone are assessed under the ICH M7 framework for carcinogenic impurity qualification. A positive Ames test result without a clear non-genotoxic mechanism triggers linear extrapolation from carcinogenicity data, with the acceptable intake derived from the TD50 or the default value of 1.5 µg/day for lifetime exposure products.
